Bill
SD 1435
Overview: SD 1435, "An Act to restore integrity in the marketing of pharmaceutical products and medical devices", has passed the House and is awaiting final concurrence.Purpose and
Overview: SD 1435, "An Act to restore integrity in the marketing of pharmaceutical products and medical devices", has passed the House and is awaiting final concurrence.
Purpose and Intent: The main goal of this bill is to address concerns about the marketing practices of pharmaceutical and medical device companies, which have been accused of engaging in deceptive or misleading promotional activities.
Key Provisions:
- Prohibits pharmaceutical and medical device companies from providing gifts, payments, or other incentives to healthcare providers
- Requires companies to disclose all payments and transfers of value to healthcare providers
- Establishes penalties for violations, including fines and potential exclusion from state healthcare programs
Affected Parties and Impacts: The primary affected parties would be pharmaceutical and medical device companies, which would face new restrictions and transparency requirements regarding their marketing and promotional activities. Healthcare providers and patients may also benefit from increased integrity and accountability in the marketing of these products.
Procedural and Timeline Considerations: The bill has passed the House and is awaiting final concurrence. Once passed, the new marketing restrictions and disclosure requirements would likely take effect within the next 6-12 months, allowing time for companies to adjust their practices.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
